Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with 161Tb and 177Lu: A Comparative Study

Conclusion: On the basis of preclinical results, [161Tb]Tb-/[177Lu]Lu-AMTG might reveal a higher therapeutic efficacy than [161Tb]Tb-/[177Lu]Lu-RM2, particularly [161Tb]Tb-AMTG because of additional Auger-electron emissions at the cell membrane level.

Source: Journal of Nuclear Medicine - March 1, 2024 Category: Nuclear Medicine Authors: Holzleitner, N., Cwojdzinski, T., Beck, R., Urtz-Urban, N., Hillhouse, C. C., Grundler, P. V., van der Meulen, N. P., Talip, Z., Ramaekers, S., Van de Voorde, M., Ponsard, B., Casini, A., Gunther, T. Tags: Brief Communications Source Type: research